Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance

被引:228
作者
He, B
Gampe, RT
Kole, AJ
Hnat, AT
Stanley, TB
An, G
Stewart, EL
Kalman, RI
Minges, JT
Wilson, EM [5 ]
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA
[4] Duke Univ, Dept Chem, Durham, NC 27710 USA
[5] Univ N Carolina, Labs Reprod Biol, Chapel Hill, NC 27599 USA
[6] GlaxoSmithKline, Discovery Res, Gene Express & Prot Biochem, Res Triangle Pk, NC 27709 USA
[7] GlaxoSmithKline, Discovery Res, Computat Chem, Res Triangle Pk, NC 27709 USA
[8] GlaxoSmithKline, Discovery Res, Struct Sci, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1016/j.molcel.2004.09.036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The androgen receptor (AR) is required for male sex development and contributes to prostate cancer cell survival. In contrast to other nuclear receptors that bind the LXXLL motifs of coactivators, the AR ligand binding domain is preferentially engaged in an interdomain interaction with the AR FXXLF motif. Reported here are crystal structures of the ligand-activated AR ligand binding domain with and without bound FXXLF and LXXLL peptides. Key residues that establish motif binding specificity are identified through comparative structure-function and mutagenesis studies. A mechanism in prostate cancer is suggested by a functional AR mutation at a specificity-determining residue that recovers coactivator LXXLL motif binding. An activation function transition hypothesis is proposed in which an evolutionary decline in LXXLL motif binding parallels expansion and functional dominance of the NH2-terminal transactivation domain in the steroid receptor subfamily.
引用
收藏
页码:425 / 438
页数:14
相关论文
共 54 条
[1]   Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition [J].
Bledsoe, RK ;
Montana, VG ;
Stanley, TB ;
Delves, CJ ;
Apolito, CJ ;
McKee, DD ;
Consler, TG ;
Parks, DJ ;
Stewart, EL ;
Willson, TM ;
Lambert, MH ;
Moore, JT ;
Pearce, KH ;
Xu, HE .
CELL, 2002, 110 (01) :93-105
[2]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[3]   Activity of the Nur1 carboxy-terminal domain depends on cell type and integrity of the activation function 2 [J].
Castro, DS ;
Arvidsson, M ;
Bolin, MB ;
Perlmann, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (52) :37483-37490
[4]  
Chang CY, 1999, MOL CELL BIOL, V19, P8226
[5]   Nuclear receptors and lipid physiology: Opening the X-files [J].
Chawla, A ;
Repa, JJ ;
Evans, RM ;
Mangelsdorf, DJ .
SCIENCE, 2001, 294 (5548) :1866-1870
[6]   MUTANT ANDROGEN RECEPTOR DETECTED IN AN ADVANCED-STAGE PROSTATIC-CARCINOMA IS ACTIVATED BY ADRENAL ANDROGENS AND PROGESTERONE [J].
CULIG, Z ;
HOBISCH, A ;
CRONAUER, MV ;
CATO, ACB ;
HITTMAIR, A ;
RADMAYR, C ;
EBERLE, J ;
BARTSCH, G ;
KLOCKER, H .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (12) :1541-1550
[7]   Structure and specificity of nuclear receptor-coactivator interactions [J].
Darimont, BD ;
Wagner, RL ;
Apriletti, JW ;
Stallcup, MR ;
Kushner, PJ ;
Baxter, JD ;
Fletterick, RJ ;
Yamamoto, KR .
GENES & DEVELOPMENT, 1998, 12 (21) :3343-3356
[8]   Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors [J].
Gampe, RT ;
Montana, VG ;
Lambert, MH ;
Miller, AB ;
Bledsoe, RK ;
Milburn, MV ;
Kliewer, SA ;
Willson, TM ;
Xu, HE .
MOLECULAR CELL, 2000, 5 (03) :545-555
[9]   Molecular biology of the androgen receptor [J].
Gelmann, EP .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :3001-3015
[10]  
Glass CK, 2000, GENE DEV, V14, P121